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Metal complexes bearing dichalcogenated imidodiphosphinate [R2P(E)NP(E)R
 
2]
− ligands (E = O, S, Se, Te), which
act as (E,E) chelates, exhibit a remarkable variety of three-dimensional structures. A series of such complexes,
namely, square-planar [Cu{(OPPh2)(OPPh2)N-O,O}2], tetrahedral [Zn{(EPPh2)(EPPh2)N-E,E}2], E = O, S, and octahedral
[Ga{(OPPh2)(OPPh2)N-O,O}3], were tested as potential inhibitors of either the platelet activating factor (PAF)- or thrombin-
induced aggregation in both washed rabbit platelets and rabbit platelet rich plasma. For comparison, square-planar
[Ni{(Ph2P)2N-S-CHMePh-P,P}X2], X = Cl, Br, the corresponding metal salts of all complexes and the (OPPh2)(OPPh2)NH
ligand were also investigated. Ga(O,O)3 showed the highest anti-PAF activity but did not inhibit the thrombin-related pathway,
whereas Zn(S,S)2, with also a signiﬁcant PAF inhibitory eﬀect, exhibited the highest thrombin-related inhibition. Zn(O,O)2 and
Cu(O,O)2 inhibited moderately both PAF and thrombin, being more eﬀective towards PAF. This work shows that the PAF-
inhibitory action depends on the structure of the complexes studied, with the bulkier Ga(O,O)3 being the most eﬃcient and
selective inhibitor.
1.Introduction
Extensive research work over the last few years has revealed
a remarkable structural variability of transition metal com-
pounds bearing dichalcogenated imidodiphosphinate type
of ligands, that is, [R2P(E)NP(E)R
 
2]
−,E= O, S, Se, Te; R,
R
  = various aryl or alkyl groups. These ligands have been
shown to display great coordinating versatility, producing
both single and multinuclear metal complexes, with a variety
of bonding modes [1–3]. The coordinating ﬂexibility of
these (E,E) chelating ligands is attributed, mainly, to their
large (ca. 4 ˚ A) E···Ebite, which would accommodate a
range of coordination sphere geometries. For instance, it
was recently shown that the [ iPr2P(Se)NP(Se) iPr2]
− ligand
aﬀords both tetrahedral and square-planar complexes of
Ni(II) [4], in agreement with an earlier observation on
the analogous [Ph2P(S)NP(S)Ph2]
− ligand [5]. Moreover,
the nature of the R and R
  peripheral groups of the
[R2P(S)NP(S)R
 
2]
− ligand has been shown to aﬀect the
geometry of the complexes formed upon its coordination
to Ni(II) [6, 7]. In a more general sense, depending on
the nature of the metal ion, the chalcogen E atom and the
R peripheral group, complexes bearing the above type of
ligands were shown to contain rather diverse coordination
spheres [8]. Such structural diﬀerences are of signiﬁcant
importance, as they are expected to lead not only to
diﬀerent stereochemical characteristics, but also to varied
electronic properties of the metal site, which, in turn,
could potentially result in signiﬁcant biological reactivity
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The aim of this work was to investigate a series of
structurally diverse metal coordination compounds bear-
ing dichalcogenated imidodiphospinate ligands, as poten-
tial inhibitors of PAF (1-O-alkyl-2-acetyl-sn-glycero-3-
phosphocholine). PAF is a phospholipid signalling molecule
of the immune system and a signiﬁcant mediator of inﬂam-
mation. PAF transmits outside-in signals to intracellular
transduction systems in a variety of cell types, including key
cells of the innate immune and haemostatic systems, such as
neutrophiles, monocytes, and platelets [10, 11]. In addition,
it exhibits biological activity through speciﬁc membrane
PAF-receptors, coupled with G-proteins. The binding of PAF
on its receptor induces intracellular signaling pathways that
lead to several cellular activation mechanisms, depending
on the cell or tissue type [12]. It is well established that
increased PAF-levels in blood or tissues lead to various
inﬂammatorymanifestations[10–12]suchascardiovascular,
renal and periodontal diseases [13–16], allergy [17], diabetes
[18], cancer [19] and AIDS [20].
A great variety of chemical compounds, both natural and
synthetic, have demonstrated an inhibitory eﬀect towards
the PAF-induced biological activities, acting either through
directantagonistic/competitiveeﬀectsbybindingtothePAF-
receptor, or through indirect mechanisms. In the latter case,
the biofunctionality seems to correlate with changes in the
membrane microenvironment of the PAF-receptor. Natural
and synthetic PAF antagonists exhibit variable chemical
structures that might lead to diﬀerent pharmacological
proﬁles. Since PAF is assumed to play a central role in
many diseases, the eﬀects of its antagonists have been widely
studiedinexperimentallyinducedpathologiesandinclinical
studies [21–24].
The use of metal complexes as potential pharmaceutics is
increasingly gaining ground [25, 26]. Particularly, complexes
of Ga(III) bearing (O,O) chelating ligands have been studied
thoroughly as promising nonplatinum compounds with
superior anticancer activity and lower side eﬀects [27, 28].
These complexes have also shown anti-inﬂammatory activity
towards reumatoidis arthritis or Alzheimer’s disease [25].
Cu(II)complexeshavebeeninvestigatedasanticanceragents,
based on the assumption that endogenous metals may be
less toxic [29]. In addition, Ni(II) and Cu(II) complexes
have been screened for their in vitro antibacterial and
antifungal activity [30], whereas Zn(II) complexes have been
investigated as agents against diabetes mellitus and ulcer
[31]. A mechanistic understanding of how metal complexes
exhibit their biological activity is crucial to their clinical
success, as well as to the rational design of new compounds
with improved pharmacological properties. In that respect,
the in vitro investigation of novel metal complexes with
targeted biomolecules may prove extremely valuable, before
the in vivo tests in animal models.
In this study, we examined the in vitro eﬀects of repre-
sentative bis- or tris-chelated complexes of dichalcogenated
imidodiphosphinate ligands, involving Cu(II), Zn(II) and
Ga(III) centers, against PAF-induced biological activities.
For this purpose, the potent inhibitory eﬀect of these metal
complexes was studied on PAF-induced platelet aggregation
towards both washed rabbit platelets (WRPs) and rabbit
platelet rich plasma (PRP). The complexes investigated con-
tain diverse metal coordination spheres, exhibiting square-
planar, tetrahedral and octahedral geometries. In addition,
twosquare-planarcomplexesofNi(II),bearingonebidentate
diphosphinoamine ligand [32] and two halide ions were also
investigated, with a view of revealing the necessary structural
features, among this set of coordination compounds, that
would ensure eﬃcient and selective inhibition of PAF.
Moreover, the inhibitory action of some of these complexes
towards thrombin was also investigated, in order to probe
their selectivity with respect to either the PAF- or the
thrombin-dependent platelet aggregation.
2. ExperimentalPart
2.1. Materials and Methods. The following complexes
were prepared according to published procedures: [Cu
{(OPPh2)(OPPh2)N-O,O}2][ 33], [Zn{(OPPh2)(OPPh2)
N-O,O}2][ 34], [Zn{(SPPh2)(SPPh2)N-S,S}2][ 35], [Ga
{(OPPh2)(OPPh2)N-O,O}3][ 36], [Ni{(Ph2P)2N-S-
CHMePh-P,P}Cl2][ 37]. These complexes are abbreviated
as Cu(O,O)2, Zn(O,O)2, Zn(S,S)2, Ga(O,O)3 and Ni(P,P)Cl2,
respectively. The synthesis of the analogous to Ni(P,P)Cl2,
bromide-containing Ni(P,P)Br2 complex, was carried
out according to the published procedure [37], with
the exception of using Ni(DME)Br2 (DME = 1,2-
dimethoxyethane) as a starting material. The detailed
synthesis and characterization of Ni(P,P)Br2 will be
described elsewhere. The (OPPh2)(OPPh2)NH ligand
was prepared as described in the literature [38]. The
following metal salts, CuCl2,Z n C l 2,G a ( N O 3)3·9H2Oa n d
NiCl2·6H2O, were also tested for comparison purposes. All
chemical reagents used were purchased from Sigma-Aldrich
(St. Louis, Mo, USA).
UV-vis spectra were recorded in a Varian Cary 3E
spectrophotometer.
Bovine serum albumin (BSA), PAF (1-O-hexadecyl-2-
acetyl-sn-glycero-3-phosphocholine), thrombin and analyt-
ical solvents for the biological assays were purchased from
Sigma.
Centrifugations were performed in a Heraeus Labofug
400R and a Sorvall RC-5B refrigerated super-speed cen-
trifuge (Sigma-Aldrich). Aggregation studies were per-
formed in a Chrono-Log aggregometer (model 400, Haver-
town, Pa, USA) coupled to a Chrono-Log recorder (Haver-
town) at 37
◦C with constant stirring at 1200rpm.
2.2. Biological Assay on WRPs and Rabbit PRP. The potential
inhibitory eﬀect of a range of metal complexes towards
PAF-related biological activities was estimated by biological
assays based on WRPs aggregation [10]. The examined
metal complexes were ﬁrst dissolved in dimethylsulfoxide
(DMSO), at an initial concentration of (4–8) × 10−3 M.
Subsequently, diﬀerent aliquots of the complexes’ solutions
were added in a BSA solution (2.5mgBSA/mL of saline).
PAF was also dissolved in the same BSA solution. The
metal salts were dissolved in saline. The platelet aggregation
induced by PAF (4.4 × 10−11 M ﬁnal concentration in theBioinorganic Chemistry and Applications 3
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Figure 1: Crystal structure of [Cu{(OPPh2)(OPPh2)N-O,O}2]
[33]. Color code: Cu (brown), O (red), P (orange), N (light blue),
C( g r e y ) .
aggregometer cuvette) or by thrombin (0.1IU) on WRPs,
was measured before (considered as 0% inhibition) and
after the addition of the sample examined. A linear plot of
inhibition percentage (ranging from 20% to 80%) versus the
concentration of the sample was established for each metal
complex. From this curve, the concentration of the sample
that inhibited 50% of the PAF-induced aggregation (IC50)
was calculated. Biological assays were performed several
times (n>3), according to methods of Demopoulos et al.
[10] and Lazanas et al. [39], so as to ensure reproducibility.
The same procedure was also followed in the case of rabbit
PRP, as previously described [40].
2.3. Statistical Methods. All results were expressed as mean ±
standard deviation (SD). The t-test was employed to assess
diﬀerences among the IC50 values of each metal complex
against either the PAF- or thrombin-induced aggregation.
Diﬀerences were considered to be statistically signiﬁcant
when the statistical p value was smaller than 0.05. Data
were analyzed using a statistical software package (SPSS for
Windows, 16.0, 2007, SPSS Inc. Chicago, IL) and Microsoft
Excel 2007.
3. Results
3.1. Molecular Structures and Stability of the Complexes.
The crystallographic structures of Cu(O,O)2 [33], Zn(O,O)2
[34], Ga(O,O)3 [36] and Ni(P,P)Cl2 [37], as well as
the (OPPh2)(OPPh2)NH ligand [41]h a v eb e e na l r e a d y
described (Figures 1–5) .Av a ri etyo fm et a lc o r eg e o m etri e si s
demonstrated: Cu(O,O)2 and Ni(P,P)Cl2 are square-planar,
whereasZn(O,O)2 istetrahedralandGa(O,O)3 isoctahedral.
The Zn(S,S)2 and Ni(P,P)Br2 complexes are expected to be
structurallysimilartoZn(O,O)2 andNi(P,P)Cl2,r especti v ely .
UV-vis absorption spectra of the light blue DMSO solutions
of Cu(O,O)2 conﬁrmed that the complex was stable for the
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Figure 2: Crystal structure of [Zn{(OPPh2)(OPPh2)N-O,O}2]
[34]. Color code: Zn (pink), O (red), P (orange), N (light blue),
C( g r e y ) .
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Figure 3: Crystal structure of [Ga{(OPPh2)(OPPh2)N-O,O}3]
[36]. Color code: Ga (pink), O (red), P (orange), N (light blue),
C( g r e y ) .
time-span of the study. This is expected since Cu(O,O)2
and the rest of the dichalcogenated imidodiphosphinate
complexes, contain highly stable six-membered M-E-P-N-P-
E chelating rings [1, 2]. On the other hand, for Ni(P,P)2X2,
X = Cl, Br, the intensity of the absorption maximum
was gradually decreasing. Therefore, degradation of the4 Bioinorganic Chemistry and Applications
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Figure 4: Crystal structure of [Ni{(Ph2P)2N-S-CHMePh-P,P}Cl2]
[37]. Color code: Ni (green), Cl (light green), P (orange), N (light
blue), C (grey).
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Figure 5: Crystal structure of the (OPPh2)(OPPh2)NH ligand [41].
Color code: O (red), P (orange), N (light blue), C (grey).
complexes at some extent is likely, which is expected to aﬀect
their inhibitory action.
3.2. Inhibitory Eﬀect of Metal Complexes and Metal Salts
towards the PAF-Induced WRP’s Aggregation. All metal
complexes under investigation inhibited the PAF-induced
aggregation of WRPs. This inhibitory eﬀect was expressed
by their IC50 value (Figure 6). Among the metal complexes
tested, Ga(O,O)3 exhibited the strongest inhibitory eﬀect
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Figure6:Theinhibitoryeﬀectofmetalcomplex estowardstheP AF-
induced WRP’s aggregation.
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Figure 7: The inhibitory eﬀect of metal salts towards the PAF-
induced WRP’s aggregation.
towards the PAF-induced WRP’s aggregation, with an IC50
value of 62.4 ± 45.0nM, which is more than one order of
magnitude lower compared to the IC50 value of the other
complexes tested. The Cu(O,O)2, Zn(O,O)2 and Zn(S,S)2
complexes also exhibited a signiﬁcant inhibitory eﬀect, with
IC50 values (300–600μM) being more than one order of
magnitude smaller compared to the value of the Ni(P,P)Cl2
and Ni(P,P)Br2 complexes.
In order to assess whether the observed inhibitory eﬀect
of the metal complexes was due to their properties—
mainly their three-dimensional structure—we also tested
the corresponding metal salts. All metal salts examined
exhibited a weak inhibitory eﬀect, with their IC50 values
ranging between 0.1 and 1mM (Figure 7), signiﬁcantly
lower than those of the corresponding metal complexes
(p < 0.001) (Figure 6). Moreover, since Ga(O,O)3 showedBioinorganic Chemistry and Applications 5
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Figure8:Theinhibitoryeﬀectofmetalcomplex estowardstheP AF-
induced rabbit PRP aggregation.
Table 1: The inhibitory eﬀect of metal complexes towards the
thrombin-induced WRP’s aggregation.
Metal complex IC50 value (μM)
Ga(O,O)3 —
Cu(O,O)2 7.86 ± 4.77
Zn(O,O)2 12.80 ± 5.62
Zn(S,S)2 0.594 ± 0.41
the most prominent inhibitory eﬀect, we also examined
the corresponding (OPPh2)(OPPh2)NH ligand, which has
already been structurally characterized [41]. This compound
exhibited a signiﬁcantly smaller inhibitory eﬀect (two orders
of magnitude) against PAF (IC50 = 1.57 ± 0.37μM) com-
pared with the Ga(O,O)3 complex (p < 0.001). This ligand’s
IC50 value is clearly smaller than those of the metal salts,
but signiﬁcantly greater than those of the Cu(O,O)2 and
Zn(O,O)2 complexes (p < 0.05).
3.3. Inhibitory Eﬀect of Metal Complexes and Metal Ions
againsttheThrombin-InducedWRP’sAggregation. Themetal
complexes exhibiting the stronger inhibitory eﬀect against
the PAF-induced WRP’s aggregation were further tested
for their potential inhibitory eﬀect towards the thrombin-
induced WRP’s aggregation [10]. The data of Table 1 show
that, among all complexes tested, Ga(O,O)3 did not inhibit
thrombin, even at concentrations up to 10−4 M, while
Zn(S,S)2 showedthestrongestinhibitoryeﬀect,displayingan
IC50 value at least one order of magnitude smaller than that
of Cu(O,O)2 and Zn(O,O)2.
3.4. Inhibitory Eﬀect of Metal Complexes and Metal Ions
against the PAF-Induced Rabbit PRP Aggregation. The metal
complexes that inhibited the PAF-induced WRP’s aggrega-
tion were further tested for their potential inhibitory eﬀect
against the PAF-induced rabbit PRP aggregation. All metal
complexes indeed showed such inhibitory behavior, with
IC50 values presented in Figure 8. The Ga(O,O)3, Zn(S,S)2
and Ni(P,P)Br2 complexes exhibited the highest inhibitory
eﬀect, since their IC50 values were signiﬁcantly lower than
that of all the other complexes tested (p < 0.05).
Moreover, we also tested the potential inhibitory eﬀect
of the corresponding metal salts. From all metal salts tested,
only CuCl2 exhibited a weak inhibitory eﬀect (IC50 = 12.3
± 1.13mM), three orders of magnitude larger than that of
its corresponding Cu(O,O)2 complex (p < 0.001). On the
contrary, the Ga(III), Ni(II) and Zn(II) salts did not inhibit
the PAF-induced aggregation of rabbit PRP. Similarly, the
(OPPh2)(OPPh2)NH ligand did not show such an inhibitory
action.
4. Discussion
The successful application of several anti-PAF agents [11–
24], and metal complexes [25–31] towards various inﬂam-
matory pathological situations, led us to study the eﬀect of
the metal complexes described above towards PAF-related
biological activities. In that respect, we have primarily
studied the in vitro eﬀects of these compounds on the PAF-
induced platelet aggregation. We have previously showed
that cis-[RhL2Cl2]Cl, L = 2-(2’-pyridyl)quinoxaline, is a
potent inhibitor of this type, having an IC50 value of 210nM
(at 0.02nM PAF), with the inhibitory eﬀect taking place,
partly, through the PAF-receptor dependent way [42].
In this study, the biological assays were focused on the
PAF-induced WRP’s and rabbit PRP aggregation. In particu-
lar, our study on WRPs probes the anti-PAF activity of metal
complexes under the experimental conditions applied, while,
in the case of rabbit PRP, the conclusions drawn pinpoint
the eﬀect of these compounds towards the PAF activation
at more similar to the in vivo conditions. Our work leads to
the unprecedented conclusion that several metal complexes
inhibited the PAF-induced aggregation towards both WRPs
and rabbit PRP, in a dose-dependent manner. Signiﬁcantly
higher concentrations (at least one order of magnitude)
of each compound were needed in order to inhibit the
PAF-induced aggregation of rabbit PRP, compared to those
needed in order to inhibit the corresponding aggregation of
WRPs. The metal complexes with the most prominent anti-
PAF activity were additionally tested towards the thrombin-
induced aggregation of WRPs.
The IC50 values reﬂect the inhibition strength of each
metal complex, since a low IC50 value reveals stronger
inhibition of the PAF-induced aggregation for a given metal
complex concentration. It is of signiﬁcant importance that
the IC50 values of these compounds (expressed as μM)
against the PAF-induced aggregation are comparable with
the IC50 values of some of the most potent PAF receptor
antagonists, namely WEB2170, BN52021, and Rupatadine
(0.02, 0.03 and 0.26μM, resp.) [43–45]. This observation
demonstrates that the metal complexes in question exhibit
a strong inhibitory eﬀect against the PAF activity. The
octahedral Ga(O,O)3 complex, which contains the larger
number (12) of phenyl rings in the second coordination6 Bioinorganic Chemistry and Applications
sphere (Figure 3), is clearly the bulkier compared to the rest
of the complexes studied (Figures 1, 2,a n d4). This tris-
chelated complex exhibited the strongest inhibitory eﬀect
against the PAF-induced aggregation of WRPs, with an IC50
value of 0.062 ± 0.045μM. The fact that this complex did
not inhibit the thrombin-induced aggregation of WRPs,
even at high doses, suggests that it antagonizes the platelet
aggregation through the selective inhibition of the PAF-
receptor pathway. Moreover, since the complexes of Cu(II)
(square planar) and Zn(II) (tetrahedral), bearing the same
(OPPh2)(OPPh2)NH ligand, exhibited an appreciable but
lower inhibitory eﬀect against the PAF-induced aggregation
of both WRPs and rabbit PRP compared to Ga(O,O)3,
it is concluded that this action depends primarily on the
complexes’three-dimensionalstructure.Thisproposalisalso
supported by the fact that the corresponding metal salts
either inhibited weakly the PAF-induced WRP’s aggregation,
or showed no inhibitory action at all when tested in rabbit
PRP. As far as the inhibitory eﬀect of ZnCl2 is concerned, our
results are consistent with those reported earlier [46].
It should be stressed that, even though the
(OPPh2)(OPPh2)NH ligand (Figure 5) inhibited the PAF-
induced aggregation of WRPs, this eﬀect was signiﬁcantly
less prominent compared with the eﬀects observed in
the case of the metal complexes studied. In addition, this
ligand did not inﬂuence the PAF-induced aggregation of
rabbit PRP, a fact that conﬁrms the importance of speciﬁc
structural characteristics of the inhibitors. Moreover,
it emphasizes that the coordination of metal ions to
ligands, each separately showing some PAF-inhibitory
action, enhances these inhibitory properties. Similar
phenomena of pharmacological proﬁle enhancement are
also reported in the case of classic anti-inﬂammatory
drugs like indomethacin, as well as antioxidants such as
bioﬂavonoid rutin and naringin, coordinated to transition
metals [47–50]. Similar behavior was also established in the
case of Cu(II) and Pt(II) complexes with various ligands
[25, 50–52].
Besides their anti-PAF activity, Cu(O,O)2 and Zn(O,O)2
inhibited also the thrombin-induced aggregation of WRPs,
but at higher concentrations than those tested against PAF,
suggesting that these metal complexes exhibit a more general
anti-inﬂammatory action, which, however, is more speciﬁc
towards the PAF-related pathway. As far the tetrahedral
Zn(S,S)2 complex is concerned, it exhibited the highest
inhibitory eﬀect against the PAF-induced aggregation of
rabbit PRP, even when compared with that of Ga(O,O)3.
At the same time, this complex showed also a strong
inhibitory eﬀect against the PAF-induced aggregation of
WRPs, which although lower than that of Ga(O,O)3,i ti s
almost twice as strong (statistically borderline signiﬁcant
with p = 0.065) than that of Zn(O,O)2 and Cu(O,O)2.
Also, this complex inhibited strongly the thrombin-induced
aggregation of WRPs, at similar concentrations with those
tested against PAF in WRPs, having an IC50 value at least
one order of magnitude lower than those of Zn(O,O)2
and Cu(O,O)2. This result suggests that Zn(S,S)2 exhibits a
more general anti-inﬂammatory activity, since it can equally
inhibit both the PAF and thrombin-related activities. Taking
also into account that in severe inﬂammatory procedures
implicated in cancer situations like melanoma, the PAF- and
thrombin-activated pathways are interrelated, thus regulat-
ing, for instance, both the melanoma cell adhesion and its
metastasis [53, 54], compounds such as Zn(S,S)2, Zn(O,O)2
and Cu(O,O)2, with inhibitory eﬀects towards both PAF
and thrombin-related activities, are promising candidates as
potential anticancer or antithrombotic agents.
Regarding the square-planar complexes of Ni(II) studied
in this work, both Ni(P,P)Cl2 and Ni(P,P)Br2 only weakly
inhibited the PAF-induced aggregation of WRPs compared
with the imidodiphosphinate-containing complexes. The
gradual degradation of these complexes in DMSO, docu-
mentedbytheirUV-visspectra,isthemostlikelyexplanation
for this observation. However, the fact that, in the case of
rabbit PRP, the Ni(P,P)Br2 complex exhibited a noticeable
inhibitory eﬀect against the PAF-induced aggregation, at lev-
elscomparabletothoseofGa(O,O)3 andZn(S,S)2 (Figure 8),
shows that the integrity of its structure is suﬃciently
retained. The observed instability of Ni(P,P)X2,X= Cl, Br, in
DMSOrendersthemunsuitableforinhibitoryaction,atleast
under the conditions employed in this work. Therefore, the
thrombin-induced WRP’s aggregation by these complexes
was not investigated.
5. Conclusions
A series of metal complexes, bearing dichalcogenated imi-
dodiphosphinate ligands, inhibited the PAF-induced aggre-
gation of both WRPs and rabbit PRP, at concentrations
comparable with those of classical PAF-inhibitors. The
compounds with the stronger anti-PAF activities exhibited
diﬀerent speciﬁcity against the thrombin-induced platelet
aggregation: Ga(O,O)3, with the highest anti-PAF activity,
did not inhibit the thrombin-related pathway, whereas
Zn(S,S)2, with also a strong inhibitory eﬀect against PAF,
exhibited the highest inhibition against thrombin. On the
other hand, Zn(O,O)2 and Cu(O,O)2 inhibited moderately
both PAF and thrombin, being more eﬀective towards
PAF. The metal salts and the (OPPh2)(OPPh2)NH ligand
showed no appreciable anti-PAF or antithrombin activity. By
comparing the relative inhibitory activities of all compounds
studied, it is concluded that the biological activities of
the metal complexes depend, at least in part, on their
stereochemical properties. In this respect, the more spherical
and bulky structure of Ga(O,O)3 seems to be the most
suitable for a PAF-related inhibitory action. On the contrary,
this complex is totally inactive towards the thrombin-related
pathway. Whether this remarkable selectivity is indeed due
to a more eﬃcient interaction of Ga(O,O)3 with the PAF-
receptor, remains to be investigated in future studies. It is
of interest that similar tris-chelated Ga(III) complexes have
shown signiﬁcant pharmaceutical action towards various
pathological cases [27, 28]. The exploration of additional
complexes of variable metal ions and three-dimensional
structures is clearly needed, in an eﬀort to further elucidate
thenecessaryelectronicorstructuralfeaturesforasigniﬁcant
and selective PAF- or thrombin-related inhibitory function.Bioinorganic Chemistry and Applications 7
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